We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Cisbio Bioassays Strengthens Presence in Asia

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "Cisbio Bioassays Strengthens Presence in Asia"

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:
Cisbio Bioassays, a member of IBA group and global developer of HTRF® (Homogeneous Time-Resolved Fluorescence) technology and services used in assay development and drug screening, has announced that it has established sales operations in China and South Korea, expanding its global presence in Asia.

The local sales teams will enable the company to offer its GPCR and kinase technology platforms, biomarker assays and related services to customers.

Sales of Cisbio Bioassays’ HTRF-based tools, which include IP-One, cAMP and Cellul’erk assays and the Tag-lite™ cell surface receptor platform, will be handled in China by IBA China, IBA group’s Beijing-based subsidiary.

IBA China was established in 2007 to support IBA group’s Asian presence in radiopharmaceutical products, equipment, and methods dedicated to cancer diagnosis and treatment. Sales in South Korea will be handled by JCBio Co. Ltd. , a Seoul-based distributor specialized in products used by pharmaceutical and biotechnology laboratory researchers.

“For nearly a decade, we have been looking to launch on-the-ground teams in specific markets with a view to enhancing our infrastructure in Europe, North America and Asia,” said François Degorce, head of marketing at Cisbio Bioassays. “We are dedicated to being a service- and customer-oriented company with a global reach, and our local presence in China and South Korea will enable us to cultivate stronger relationships with our customers in these important markets.”

Winner of the Frost & Sullivan 2009 North American Technological Innovation of the Year Award, Cisbio Bioassays pioneered the field of homogenous fluorescence methodologies via its proprietary technology, HTRF, a highly sensitive, robust technology for the detection of molecular interactions and widely used by the pharmaceutical industry for the high throughput screening stage of drug development.

In addition to its HTRF-based tools, the company offers a range of services, including custom labeling of specific assay components, custom assay design and development, and HTRF technology training with its highly-trained technical staff. Headquartered in France, Cisbio Bioassays has facilities in Bedford, Massachusetts (USA), and markets its products through exclusive distributors in Japan and India.